The survival outcomes of localized low‐risk prostate cancer, a population‐based study using NCDB
Cancer Medicine · 2024
DOI: 10.1002/cam4.70060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Shifeng Mao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatectomy. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The optimal treatment approach for low‐risk prostate cancer (LRPC) remains controversial. While active surveillance is an increasingly popular option, definitive local treatments, including radical prostatectomy (RP), external beam radiotherapy (EBRT), and prostate seed implantation (PSI), are also commonly used. This study aimed to evaluate the survival outcomes of patients with LRPC using a large patient population from the National Cancer Database (NCDB).
Methods
We analyzed data from 195,452 patients diagnosed with LRPC between 2004 and 2015 using the NCDB. Patients were classified based on their treatment modalities, including RP, EBRT, PSI, or no local treatment (NLT). Only patients with Charlson–Deyo comorbidity scores of 0 or 1 were included to ensure comparability. Propensity score analysis was used to balance the treatment groups, and the accelerated failure time model was used to analyze the survival rates of the treatment groups.
Results
After a median follow‐up of 70.8 months, 24,545 deaths occurred, resulting in an all‐cause mortality rate of 13%. RP demonstrated a survival benefit compared with NLT, particularly in patients younger than 74 years of age. In contrast, radiation treatments (EBRT and PSI) did not improve survival in the younger age groups, except for patients older than 70 years for EBRT and older than 65 years for PSI. Notably, EBRT in patients younger than 65 years was associated with inferior outcomes.
Conclusion
This study highlights the differences in survival outcomes among LRPC treatment modalities. RP was associated with improved survival compared to NLT, especially in younger patients. In contrast, EBRT and PSI showed survival benefits primarily in the older age groups. NLT is a reasonable choice, particularly in younger patients when RP is not chosen. These findings emphasize the importance of individualized treatment decisions for LRPC management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania, USA.
- Division of Urology, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
- Allegheny-Singer Research Institute, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
- Division of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania, USA.
- Department of Pathology, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Shifeng Mao
Zitieren
APA
Mao, S., Samiei, A., Yin, Y., Wegner, R. E., Sanguino, A., Lyne, J., Miller, R., & Cohen, J. (2024). The survival outcomes of localized low‐risk prostate cancer, a population‐based study using NCDB. Cancer Medicine. https://doi.org/10.1002/cam4.70060
Vancouver
Mao S, Samiei A, Yin Y, Wegner RE, Sanguino A, Lyne J, et al. The survival outcomes of localized low‐risk prostate cancer, a population‐based study using NCDB. Cancer Medicine. 2024. doi:10.1002/cam4.70060
BibTeX
@article{Mao2024,
author = {Mao, Shifeng and Samiei, Arash and Yin, Yue and Wegner, Rodney E and Sanguino, Angela and Lyne, John and Miller, Ralph and Cohen, Jeffrey},
title = {The survival outcomes of localized low‐risk prostate cancer, a population‐based study using NCDB},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70060}
}
EUVIMED